Identification

Name
Neostigmine
Accession Number
DB01400
Type
Small Molecule
Groups
Approved, Vet approved
Description

A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]

Structure
Thumb
Synonyms
  • (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate
  • 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  • Eustigmin
  • Eustigmine
  • m-Trimethylammoniumphenyldimethylcarbamate
  • Neostigmina
Product Ingredients
IngredientUNIICASInChI Key
Neostigmine bromide005SYP50G5114-80-7LULNWZDBKTWDGK-UHFFFAOYSA-M
Neostigmine methylsulfate98IMH7M38651-60-5OSZNNLWOYWAHSS-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BloxiverzInjection1 mg/1mLIntravenousAvadel Legacy Pharmaceuticals, Llc2013-07-24Not applicableUs
BloxiverzInjection1 mg/1mLIntravenousAvadel Legacy Pharmaceuticals, Llc2013-07-24Not applicableUs
BloxiverzInjection0.5 mg/1mLIntravenousAvadel Legacy Pharmaceuticals, Llc2013-07-24Not applicableUs
BloxiverzInjection0.5 mg/1mLIntravenousAvadel Legacy Pharmaceuticals, Llc2013-07-24Not applicableUs
BloxiverzInjection1 mg/1mLIntravenousBluePoint Laboratories2017-06-30Not applicableUs
Neostigmine MethylsulfateInjection, solution0.5 mg/1mLIntravenousFresenius Kabi2015-01-08Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/1mLIntravenousGeneral Injectables & Vaccines2016-08-11Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/1mLIntravenousFresenius Kabi2015-01-08Not applicableUs
Neostigmine MethylsulfateInjection, solution1 mg/1mLIntravenousRemedy Repack2015-10-19Not applicableUs
Neostigmine Methylsulfate Inj 0.5mg/ml USPLiquid.5 mgIntramuscular; Intravenous; SubcutaneousDavid Bull Laboratories (Pty) Ltd.1992-12-311996-09-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NeostigmineInjection1 mg/1mLIntravenousDr.Reddy's Laboratories Inc2018-09-04Not applicableUs
NeostigmineInjection0.5 mg/1mLIntravenousDr.Reddy's Laboratories Inc2018-09-04Not applicableUs
Neostigmine MethylsulfateInjection1 mg/1mLIntravenousWest-Ward Pharmaceuticals Corp.2015-12-28Not applicableUs
Neostigmine MethylsulfateInjection1 mg/1mLIntravenousAMERICAN REGENT, INC.2018-05-14Not applicableUs
Neostigmine methylsulfateInjection1 mg/1mLIntravenousAmneal Biosciences Llc2018-06-20Not applicableUs
Neostigmine MethylsulfateInjection1 mg/1mLIntravenousMedical Purchasing Solutions, Llc2017-04-26Not applicableUs
Neostigmine MethylsulfateInjection1 mg/1mLIntravenousAmphastar Pharmaceuticals, Inc.2017-09-25Not applicableUs
Neostigmine MethylsulfateInjection0.5 mg/1mLIntravenousWest-Ward Pharmaceuticals Corp.2015-12-28Not applicableUs
Neostigmine MethylsulfateInjection0.5 mg/1mLIntravenousAMERICAN REGENT, INC.2018-05-14Not applicableUs
Neostigmine methylsulfateInjection0.5 mg/1mLIntravenousAmneal Biosciences Llc2018-06-20Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Neostigmine MethylsuflateNeostigmine methylsulfate (1 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines2010-08-012014-08-31Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousClaris Lifesciences Limited2009-10-092010-11-04Us
Neostigmine MethylsulfateNeostigmine methylsulfate (0.5 mg/1mL)InjectionIntramuscular; Intravenous; SubcutaneousWest-Ward Pharmaceuticals Corp.1973-01-012016-04-30Us
Neostigmine MethylsulfateNeostigmine methylsulfate (0.5 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousClaris Lifesciences, Inc.2009-10-072010-11-04Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)Injection, solutionIntravenousCantrell Drug Company2015-02-032017-12-06Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousAmerican Regent2003-01-162016-10-17Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)InjectionIntramuscular; Intravenous; SubcutaneousCardinal Health1973-01-012014-09-30Us
Neostigmine MethylsulfateNeostigmine methylsulfate (0.5 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousClaris Lifesciences Limited2009-10-072010-11-04Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)InjectionIntramuscular; Intravenous; SubcutaneousWest-Ward Pharmaceuticals Corp.1973-01-012015-08-31Us
Neostigmine MethylsulfateNeostigmine methylsulfate (1 mg/1mL)Injection, solutionIntramuscular; Intravenous; SubcutaneousFresenius Kabi2000-09-012016-11-18Us
International/Other Brands
Prostigmin / Vagostigmin
Categories
UNII
3982TWQ96G
CAS number
59-99-4
Weight
Average: 223.2915
Monoisotopic: 223.144652862
Chemical Formula
C12H19N2O2
InChI Key
ALWKGYPQUAPLQC-UHFFFAOYSA-N
InChI
InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
IUPAC Name
3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium
SMILES
CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C

Pharmacology

Indication

Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.

Associated Conditions
Pharmacodynamics

Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.

Mechanism of action

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.

TargetActionsOrganism
AAcetylcholinesterase
inhibitor
Human
Absorption

Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration

Volume of distribution
Not Available
Protein binding

Protein binding to human serum albumin ranges from 15 to 25 percent.

Metabolism

Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.

Route of elimination
Not Available
Half life

The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.

Clearance
Not Available
Toxicity

Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously, and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously, and 0.423 ± 0.032 mg/kg intramuscularly.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbemaciclibThe serum concentration of Neostigmine can be increased when it is combined with Abemaciclib.
AcebutololNeostigmine may increase the bradycardic activities of Acebutolol.
AcetaminophenThe serum concentration of Neostigmine can be increased when it is combined with Acetaminophen.
AcetylcholineThe risk or severity of adverse effects can be increased when Neostigmine is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Neostigmine.
AfatinibThe serum concentration of Neostigmine can be increased when it is combined with Afatinib.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Neostigmine.
AlbendazoleThe serum concentration of Neostigmine can be increased when it is combined with Albendazole.
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Neostigmine.
AldosteroneThe serum concentration of Neostigmine can be decreased when it is combined with Aldosterone.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015472
KEGG Compound
C07258
PubChem Compound
4456
PubChem Substance
46509161
ChemSpider
4301
BindingDB
50022775
ChEBI
7514
ChEMBL
CHEMBL278020
Therapeutic Targets Database
DAP000563
PharmGKB
PA450611
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Neostigmine
ATC Codes
N07AA51 — Neostigmine, combinationsS01EB06 — NeostigmineN07AA01 — Neostigmine
AHFS Codes
  • 12:04.00 — Parasympathomemetic (Cholinergic) Agents
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentNeurogenic Bowel Dysfunction / Spinal Cord Injuries (SCI)1
0Not Yet RecruitingPreventionIncidence of Postoperative Residual Curarization1
0RecruitingTreatmentSnoring1
1CompletedTreatmentLabour Pain1
1Not Yet RecruitingTreatmentAcute Pancreatitis (AP) / Intra-Abdominal Hypertension1
1RecruitingNot AvailableGastrointestinal Dysfunction1
1, 2CompletedSupportive CareAdjunct to general anesthesia therapy / Smooth muscle relaxation prior to radiological procedures1
2Not Yet RecruitingPreventionCurarization, Postoperative Residual2
2RecruitingSupportive CareCancer, Breast1
2, 3Active Not RecruitingPreventionAdjuvants, Anesthesia1
2, 3CompletedPreventionHypospadias1
2, 3CompletedTreatmentKnee Injuries1
2, 3RecruitingTreatmentPostoperative pain1
2, 3Unknown StatusTreatmentNeuromuscular Blockade / Obesity, Morbid1
3Active Not RecruitingTreatmentMinor burns1
3CompletedPreventionPost-Operative Nausea and Vomiting (PONV)1
3CompletedTreatmentAnaesthesia therapy2
3CompletedTreatmentAntithrombotic Agents / Arthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee / Coagulation, Blood / Neuromuscular Blockade1
3CompletedTreatmentDiaphragmatic Dysfunction / Muscle Fatigue / Muscle Weakness1
3CompletedTreatmentNeuromuscular Blockade2
3CompletedTreatmentAdjunct to general anesthesia therapy / Neuromuscular Blockade1
3CompletedTreatmentSurgical Procedures, Elective1
3CompletedTreatmentAdjunct to general anesthesia therapy4
3RecruitingTreatmentGeneral Surgery1
4Active Not RecruitingPreventionNeuromuscular Blockade / Postoperative Complications1
4Active Not RecruitingSupportive CareMuscle Relaxation1
4CompletedBasic ScienceElectromyography / Respiratory Muscles1
4CompletedDiagnosticIntraocular Pressure Changes During Tracheal Extubation1
4CompletedDiagnosticSphincter of Oddi Dysfunction1
4CompletedDiagnosticSpinal Cord Injuries (SCI)1
4CompletedPreventionIncidence of Postoperative Nausea and Vomiting1
4CompletedScreeningSpinal Curvatures1
4CompletedSupportive CareBMI >30 kg/m2 / Cerebral Tissue Oxygenation / Laparoscopic Gastric Bypass Surgery / Respiratory Function / Surgical Conditions1
4CompletedSupportive CareIleus1
4CompletedTreatmentAirway Reflexes, Protective / Anesthetic Recovery / Recovery After Neuromuscular Block1
4CompletedTreatmentAnaesthesia1
4CompletedTreatmentAnesthesia Recovery1
4CompletedTreatmentCaesarean Sections / Pregnancy1
4CompletedTreatmentCirrhosis and Chronic Liver Disease1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentIncomplete Reversal of Neuromuscular Block1
4CompletedTreatmentMajor Abdominal Surgery1
4CompletedTreatmentNeuromuscular Block1
4CompletedTreatmentObstructive Sleep Apnea (OSA)1
4CompletedTreatmentParalysis1
4CompletedTreatmentPostoperative Respiratory Condition1
4CompletedTreatmentRespiratory-Gated Imaging Techniques1
4CompletedTreatmentReversal of Skeletal Muscle Relaxant / Underdosing of Skeletal Muscle Relaxants for Laparotomy1
4CompletedTreatmentSpine Surgery1
4Enrolling by InvitationTreatmentNeuromuscular Blockade1
4Not Yet RecruitingDiagnosticResidual Neuromuscular Blockade1
4Not Yet RecruitingPreventionPulmonary Complications1
4Not Yet RecruitingTreatmentObstructive Sleep Apnea (OSA)1
4Not Yet RecruitingTreatmentPattern of GIT Motility1
4Not Yet RecruitingTreatmentRespiratory Insufficiency1
4RecruitingOtherNeuromuscular Blockade1
4RecruitingPreventionEmergence Delirium1
4RecruitingPreventionPost-Dural Puncture Headache1
4RecruitingSupportive CareBladder Cancers / Malignant Neoplasms of Urinary Tract1
4RecruitingTreatmentAnaesthesia therapy / Neuromuscular Blockade1
4RecruitingTreatmentAnesthesia Recovery Period / Laparoscopy1
4RecruitingTreatmentAnesthesiology Management1
4RecruitingTreatmentMalignant Neoplasms of Digestive Organs / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Urinary Tract1
4RecruitingTreatmentMicrolaryngoscopy / Rigid Bronchoscopy1
4RecruitingTreatmentNeuromuscular Blockade4
4RecruitingTreatmentPost-Operative Nausea and Vomiting (PONV) / Respiratory Conditions Due to Other External Agents1
4RecruitingTreatmentPost-operative Residual Curarization1
4RecruitingTreatmentReversal of Neuromuscular Blockade1
4Unknown StatusSupportive CareAnesthesia Recovery Period1
4Unknown StatusTreatmentNeuromuscular Blockade1
4WithdrawnNot AvailableNeuromuscular Blockade1
Not AvailableActive Not RecruitingNot AvailableNeuromuscular Blockade1
Not AvailableCompletedNot AvailableNeuromuscular Blockade1
Not AvailableCompletedNot AvailableResidual Neuromuscular Block (TOF-ratio of 0.2)1
Not AvailableCompletedOtherAnesthesiology Management1
Not AvailableCompletedPreventionElderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia1
Not AvailableCompletedScreeningPost Operative Cognitive Dysfunction1
Not AvailableCompletedSupportive CareResidual Neuromuscular Block1
Not AvailableCompletedSupportive CareRobot-Assisted Laparoscopic Radical Prostatectomy1
Not AvailableCompletedTreatmentNeuromuscular Blockade1
Not AvailableCompletedTreatmentObesity, Morbid / Respiratory Complications1
Not AvailableCompletedTreatmentObservation of Neuromuscular Block1
Not AvailableCompletedTreatmentAdjunct to general anesthesia therapy1
Not AvailableEnrolling by InvitationSupportive CareSupratentorial Brain Tumor Surgery1
Not AvailableRecruitingNot AvailableResidual Neuromuscular Blockade1
Not AvailableRecruitingDiagnosticBlood Coagulation Tests ( INR, APTT)1
Not AvailableRecruitingOtherPostoperative Residual Curarization / Transplantation, Liver1
Not AvailableUnknown StatusTreatmentPregnancy / Vaginal Delivery1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • Pharmedium
  • Spectrum Pharmaceuticals
  • Valeant Ltd.
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous; Subcutaneous0.5 mg/1mL
InjectionIntramuscular; Intravenous; Subcutaneous1 mg/1mL
InjectionIntravenous0.5 mg/1mL
InjectionIntravenous1 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous0.5 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous1 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous5 mg/1mL
Injection, solutionIntravenous0.5 mg/1mL
Injection, solutionIntravenous1 mg/1mL
SolutionIntramuscular; Intravenous; Subcutaneous0.5 mg
SolutionIntramuscular; Intravenous; Subcutaneous2.5 mg
LiquidIntramuscular; Intravenous; Subcutaneous0.5 mg
LiquidIntramuscular; Intravenous; Subcutaneous1 mg
TabletOral15 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous.5 mg
TabletOral15 mg
Prices
Unit descriptionCostUnit
Neostigmine bromide powder96.57USD g
Neostigmine ms 5 mg/5 ml syr1.99USD ml
Prostigmin 1:4000 ampul1.42USD ml
Prostigmin 15 mg tablet1.04USD tablet
Neostigmine 1:1000 vial0.48USD ml
Neostigmine 1:2000 vial0.48USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0677 mg/mLALOGPS
logP-1.6ALOGPS
logP-2.2ChemAxon
logS-3.6ALOGPS
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity75.28 m3·mol-1ChemAxon
Polarizability25.08 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8576
Blood Brain Barrier+0.9583
Caco-2 permeable+0.608
P-glycoprotein substrateNon-substrate0.8263
P-glycoprotein inhibitor INon-inhibitor0.9598
P-glycoprotein inhibitor IINon-inhibitor0.9279
Renal organic cation transporterNon-inhibitor0.9181
CYP450 2C9 substrateNon-substrate0.7197
CYP450 2D6 substrateNon-substrate0.6869
CYP450 3A4 substrateSubstrate0.622
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9367
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8362
Ames testAMES toxic0.5146
CarcinogenicityNon-carcinogens0.5931
BiodegradationNot ready biodegradable0.7893
Rat acute toxicity2.9481 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.8738
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0090000000-7feec7180feed2165741
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0090000000-33ad4a0e0807f82bab39
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0ab9-2090000000-285ee2bce4f4c2097510
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9110000000-a2386202e9dc8c7c753f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9100000000-b80120a3f55bb762fe51
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0a4i-0090000000-675c3ee4663579ce2125

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxy compounds. These are aromatic compounds contaning a phenoxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxy compounds
Direct Parent
Phenoxy compounds
Alternative Parents
Aniline and substituted anilines / Quaternary ammonium salts / Carbamate esters / Organic carbonic acids and derivatives / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Amines
show 1 more
Substituents
Phenoxy compound / Aniline or substituted anilines / Quaternary ammonium salt / Carbamic acid ester / Carbonic acid derivative / Amine / Carbonyl group / Hydrocarbon derivative / Organic oxide / Organic salt
show 7 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
quaternary ammonium ion (CHEBI:7514)

Targets

Details
1. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Trevisani GT, Hyman NH, Church JM: Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000 May;43(5):599-603. [PubMed:10826417]
  2. Naves LA, Van der Kloot W: Repetitive nerve stimulation decreases the acetylcholine content of quanta at the frog neuromuscular junction. J Physiol. 2001 May 1;532(Pt 3):637-47. [PubMed:11313435]
  3. Takeuchi K, Kawauchi S, Araki H, Ueki S, Furukawa O: Stimulation by nizatidine, a histamine H(2)-receptor antagonist, of duodenal HCO(3)(-)secretion in rats:relation to anti-cholinesterase activity. World J Gastroenterol. 2000 Oct;6(5):651-658. [PubMed:11819669]
  4. Minic J, Chatonnet A, Krejci E, Molgo J: Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Br J Pharmacol. 2003 Jan;138(1):177-87. [PubMed:12522088]
  5. Beck KD, Brennan FX, Moldow RL, Ottenweller JE, Zhu G, Servatius RJ: Stress interacts with peripheral cholinesterase inhibitors to cause central nervous system effects. Life Sci. 2003 May 23;73(1):41-51. [PubMed:12726885]
  6. Zhang B, Hepner DL, Tran MH, Friedman M, Korn JR, Menzin J: Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. doi: 10.1185/03007990902769054 . [PubMed:19257799]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Saito S: Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons. Neurotoxicol Teratol. 1998 Jul-Aug;20(4):411-9. [PubMed:9697967]

Drug created on July 08, 2007 11:06 / Updated on November 20, 2018 13:19